Matinas BioPharma Holdings Inc. (MTNB) is a clinical-stage biopharmaceutical company based in Bedminster, New Jersey, focused on transforming drug delivery through its proprietary oral lipid-based systems, primarily targeting infectious diseases and chronic conditions. The company is dedicated to enhancing both treatment efficacy and patient adherence, addressing critical unmet medical needs in the healthcare landscape. With a robust pipeline of innovative therapeutic candidates and strategic partnerships, Matinas BioPharma represents a compelling investment prospect for institutional investors seeking growth opportunities within the biotechnology sector poised to deliver impactful patient outcomes. Show more
Location: 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ, UNITED STATES, 07921, 1545 Route 206 South, Bedminster, NJ, 07921, USA | Website: https://www.matinasbiopharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
3.664M
52 Wk Range
$0.47 - $3.09
Previous Close
$0.57
Open
$0.56
Volume
15,130
Day Range
$0.56 - $0.62
Enterprise Value
950.3K
Cash
5.435M
Avg Qtr Burn
-1.474M
Insider Ownership
22.11%
Institutional Own.
5.33%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
MAT2203 (Oral Amphotericin B) Details Meningitis, Cryptococcal meningitis, Azole-resistant infections, C. krusei infection, Fungal infections, Invasive Aspergillosis | Failed Discontinued | |
LYPDISO (MAT9001) (Omega-3 Drug) Details Cardiovascular disease | Failed Discontinued |